INO Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of 5.19%. Inovio Pharmaceuticals's return on equity of -98.72% beat Baxter International's return on equity of 1.33%.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 495.9%. On the other hand Baxter International has an analysts' consensus of -- which suggests that it could grow by 39.45%. Given that Inovio Pharmaceuticals has higher upside potential than Baxter International, analysts believe Inovio Pharmaceuticals is more attractive than Baxter International.

Inovio Pharmaceuticals has a beta of 0.749, which suggesting that the stock is 25.086% less volatile than S&P 500. In comparison Baxter International has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.462%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.56% to investors and pays a quarterly dividend of $0.17 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are smaller than Baxter International quarterly revenues of $2.7B. Inovio Pharmaceuticals's net income of -$25.2M is lower than Baxter International's net income of $140M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Baxter International's PE ratio is 145.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 0.86x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Candel Therapeutics has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of --. Inovio Pharmaceuticals's return on equity of -98.72% beat Candel Therapeutics's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 495.9%. On the other hand Candel Therapeutics has an analysts' consensus of $19.00 which suggests that it could grow by 120.16%. Given that Inovio Pharmaceuticals has higher upside potential than Candel Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Candel Therapeutics.

Inovio Pharmaceuticals has a beta of 0.749, which suggesting that the stock is 25.086% less volatile than S&P 500. In comparison Candel Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Candel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Candel Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are larger than Candel Therapeutics quarterly revenues of --. Inovio Pharmaceuticals's net income of -$25.2M is lower than Candel Therapeutics's net income of -$10.6M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Candel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 2,089.14x for Candel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of -143.53%. Inovio Pharmaceuticals's return on equity of -98.72% beat Novavax's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 495.9%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 85.19%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Inovio Pharmaceuticals has a beta of 0.749, which suggesting that the stock is 25.086% less volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are smaller than Novavax quarterly revenues of $84.5M. Inovio Pharmaceuticals's net income of -$25.2M is higher than Novavax's net income of -$121.3M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.50x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of 18.02%. Inovio Pharmaceuticals's return on equity of -98.72% beat Protalix BioTherapeutics's return on equity of -29.54%.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 495.9%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 709.25%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 0.749, which suggesting that the stock is 25.086% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Inovio Pharmaceuticals's net income of -$25.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 2.98x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.